| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.053 | 0.3 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.3 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.3 |